Stand up a hypercalcemia of malignancy protocol: fluids, calcitonin/bisphosphonates,…
- User
Stand up a hypercalcemia of malignancy protocol: fluids, calcitonin/bisphosphonates, cancer liaison, and discharge plan.
- Assistant
Hypercalcemia of Malignancy (HCM) Management Protocol
Indication: Serum calcium >12 mg/dL (or ionized Ca >1.5 mmol/L) with symptoms (e.g., nausea, confusion, polyuria) or >14 mg/dL asymptomatic, confirmed due to malignancy (e.g., PTHrP-mediated, osteolytic metastases). Rule out other causes (e.g., hyperparathyroidism via PTH level).
Severity Grading (Albumin-corrected Ca):
- Mild: 10.5–11.9 mg/dL → Outpatient if asymptomatic.
- Moderate: 12–13.9 mg/dL → Admit for IV therapy.
- Severe: ≥14 mg/dL or symptomatic → ICU if unstable (e.g., arrhythmia, coma).
Goals: Normalize Ca within 24–48h; urine output 100–150 mL/hr; maintain euvolemia.
1. Initial Assessment & Supportive Care
- Labs: CBC, CMP (q6–12h until stable), ionized Ca, PTH, PTHrP, SPEP/UPEP, 1,25-vit D, Mg, Phos. ECG (short QT, arrhythmias).
- Admit: Medicine/Oncology; telemetry if cardiac risk.
- NPO initially if severe nausea; advance as tolerated (avoid Ca/vit D supplements).
- Page Cancer Liaison/Oncology STAT for etiology workup (CT chest/abd/pelvis if unknown primary) and disease-directed therapy.
2. Fluids (First-Line, Cornerstone)
- Normal Saline (NS) 200–300 mL/hr IV (adjust for CHF/renal failure; goal UOP 2–3 mL/kg/hr).
- Monitor: Strict I/Os, daily weights, lytes q6h.
- Once euvolemic (typically 2–4L NS): Add furosemide 20–40 mg IV q6–8h if UOP low or hypervolemic.
- Avoid thiazides; replete Mg/K if low.
Expected Ca drop: 1–2 mg/dL in 12–24h.
3. Pharmacotherapy
Rapid Onset (First 24–48h)
- Calcitonin: 4 IU/kg SQ/IM q12h x 48–72h (tachyphylaxis common after 72h).
- Onset: 4–6h; peak effect: 24h.
- Monitor: Hypocalcemia risk (rare).
Definitive (Bisphosphonates; Start Day 1 after fluids)
Agent Dose Infusion Notes Zoledronic acid (Preferred) 4 mg IV Over 15 min CrCl >60: full dose; 30–60: 3.5 mg; <30: 3 mg. Max 4 mg/2wks. Pamidronate 60–90 mg IV (60 if Ca 12–14; 90 if >14) Over 2h Alternative if zoledronic unavailable. - Onset: 24–48h; duration: 2–4wks.
- Hold if CrCl <30 or acute kidney injury; hydrate pre-dose.
- Refractory/Recurrent: Denosumab 120 mg SQ q4wks (preferred in renal failure).
Adjuncts (if severe/refractory):
- Glucocorticoids (e.g., dex 4 mg q6h if granulomatous/lymphoma).
- Dialysis if Ca >18 or renal failure.
4. Monitoring & Escalation
Time Labs/Actions q6h (acute) Ca (ionized pref), lytes, Cr, UOP. q12–24h (stable) Trend Ca; ECG if QTc <350ms. Daily Weights, neuro checks. - Target: Ca <12 mg/dL (outpatient goal <11).
- Escalate: Re-page oncology if no drop >1 mg/dL in 24h.
5. Cancer Liaison Integration
- STAT consult on admission.
- Coordinate: Biopsy if undiagnosed; systemic therapy (chemo/targeted); palliative care if poor prognosis.
- Document malignancy type, prior HCM episodes.
6. Discharge Plan
Criteria:
- Asymptomatic, Ca <12 mg/dL (stable x24h).
- Tolerating PO, euvolemic, Cr stable.
- Oncology f/u within 48h.
Instructions:
-
Meds:
Med Dose Duration Zoledronic acid As above, repeat q1–4wks per oncology. Ongoing. Denosumab 120 mg SQ q4wks. Alternative. Calcitonin nasal 200 IU EN q12h x2wks (bridge). If SQ unavailable. Oral hydration ≥3L/day; avoid Ca-rich foods. Indefinite. -
Follow-up:
Provider Timing Oncology 24–48h (labs: Ca q1–2wks initially). PCP 1wk. Home Health If frail (wt, symptoms). -
Red Flags: Nausea, confusion, polyuria → ED.
-
Patient Education: "Drink fluids, watch symptoms, oncology-directed therapy prevents recurrence."
-
Labs at D/C: CMP; oncology to titrate.
Protocol Owner: Oncology. Last Updated: [Date]. References: NCCN Hypercalcemia, UpToDate HCM 2023.
Consult local guidelines/pharmacy for dosing adjustments.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.